The impact of prior bDMARD failures on efficacy and safety outcomes in patients with RA receiving the interleukin-6 inhibitor tocilizumab has also been determined in an analysis of data from an observational cohort study [47]. Here, IL6 is linked to rheumatoid arthritis.